Claudin 18.2
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
-
【ASCO Highlights】China-made First-in-Class Claudin 18.2 CAR-T Therapy Shows Promising Phase I Results!
Follow Drug Times to grasp valuable industry information at the first moment
